Corundum Systems Biology has led a seed investment in ImYoo to advance at-home health data collection and enhance personalized healthcare solutions.

Target Information

ImYoo is an innovative health technology startup that recently announced the closing of its seed funding round, led by Corundum Systems Biology with contributions from various investors including PsyMed Ventures, Freeflow Ventures, Arben Ventures, Adam Draper, and Jared Hecht. The company's primary focus lies in transforming the understanding of human health from static measurements to a dynamic, longitudinal perspective. ImYoo aspires to enable individuals to monitor their immune health at home, facilitating a real-time understanding of changing biomarker levels in response to treatment or disease progression.

Founded by Tatyana Dobreva, PhD, and David Brown, PhD, both alumni of Caltech and former engineers at NASA's Jet Propulsion Laboratory, ImYoo integrates high-dimensional immune profiling into patients' everyday lives. The duo's collective experience has enabled them to design tools for patients that they wish they had access to during their quest for autoimmune diagnostics. This drive to personalize health monitoring through innovative data integration is central to ImYoo's mission.

Industry Overview in the United States

The healthcare industry in the United States is currently experiencing a significant shift towards patient-centric models, particularly in data collection and analysis. The convergence of at-home sampling technologies, advanced molecular assays,